Recent work has indicated the ability of TKIs to strongly suppress PI3K signalling (and possibly other pro-survival pathways) in CRC, suggesting that these treatments may have great therapeutic value [68]. The gene discussed is PIK3CA; the disease is colorectal carcinoma.